The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Melanoma at ASCO 2026: IGNYTE, OptimUM-02, and a Phase I/II trial of anzu-cel
Allison Betof Warner, MD, Stanford University, Stanford, CA, discusses skin cancer highlights of the 2026 American Society of Clinical Oncology (ASCO) Meeting, including three-year follow-up from the IGNYTE trial (NCT03767348) and the OptimUM-02 trial (NCT05987332) of darovasertib and crizotinib for uveal melanoma. Additional trials of interest include a trial (NCT06743126) assessing anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy in melanoma. This interview took place during the 2026 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s been a great ASCO, both in the cutaneous oncology space and beyond, of course, some really exciting studies in sarcoma and pancreatic cancer in the plenaries. But particularly within the cutaneous space, you know, we saw data a couple days ago from the three-year follow-up from the IGNYTE study of RP1 plus nivolumab, which looks quite impressive. You know, today, of course, the groundbreaking study with darovasertib and crizotinib, which hopefully could lead to a brand-new treatment option for uveal melanoma patients, which is an area of huge unmet need...
It’s been a great ASCO, both in the cutaneous oncology space and beyond, of course, some really exciting studies in sarcoma and pancreatic cancer in the plenaries. But particularly within the cutaneous space, you know, we saw data a couple days ago from the three-year follow-up from the IGNYTE study of RP1 plus nivolumab, which looks quite impressive. You know, today, of course, the groundbreaking study with darovasertib and crizotinib, which hopefully could lead to a brand-new treatment option for uveal melanoma patients, which is an area of huge unmet need. And then some exciting updates for the PRAME TCR anzu-cel as well, presented today by Dr. Diwakar Davar.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
